Další formáty:
BibTeX
LaTeX
RIS
@article{1795084,
author = {Hussain, Mohammad Salman and Baxi, Harveen and Riad, Abanoub and Klugarová, Jitka and Pokorná, Andrea and Slezáková, Simona and Líčeník, Radim and Najmi, Abul Kalam and Klugar, Miloslav},
article_location = {Basel},
article_number = {19},
doi = {http://dx.doi.org/10.3390/ijerph181910340},
keywords = {COVID-19; diabetes; epidemiology; evidence; mortality; mucormycosis; mycoses; public health},
language = {eng},
issn = {1660-4601},
journal = {Environmental Research and Public Health},
title = {COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping},
url = {https://www.mdpi.com/1660-4601/18/19/10340},
volume = {18},
year = {2021}
}
TY - JOUR
ID - 1795084
AU - Hussain, Mohammad Salman - Baxi, Harveen - Riad, Abanoub - Klugarová, Jitka - Pokorná, Andrea - Slezáková, Simona - Líčeník, Radim - Najmi, Abul Kalam - Klugar, Miloslav
PY - 2021
TI - COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping
JF - Environmental Research and Public Health
VL - 18
IS - 19
SP - 1-18
EP - 1-18
PB - MDPI
SN - 16604601
KW - COVID-19
KW - diabetes
KW - epidemiology
KW - evidence
KW - mortality
KW - mucormycosis
KW - mycoses
KW - public health
UR - https://www.mdpi.com/1660-4601/18/19/10340
N2 - Mucormycosis, a serious and rare fungal infection, has recently been reported in COVID-19 patients worldwide. This study aims to map all the emerging evidence on the COVID-19-associated mucormycosis (CAM) with a special focus on clinical presentation, treatment modalities, and patient outcomes. An extensive literature search was performed in MEDLINE (Ovid), Embase (Ovid), Cochrane COVID-19 Study Register, and WHO COVID-19 database till 9 June 2021. The primary outcome was to summarize the clinical presentation, treatment modalities, and patient outcomes of CAM. Data were summarized using descriptive statistics and presented in tabular form. This evidence mapping was based on a total of 167 CAM patients with a mean age of 51 ± 14.62 years, and 56.28% of them were male. Diabetes mellitus (73.65% (n = 123)), hypertension (22.75% (n = 38)), and renal failure (10.77% (n = 18)) were the most common co-morbidities among CAM patients. The most common symptoms observed in CAM patients were facial pain, ptosis, proptosis, visual acuity, and vision loss. Survival was higher in patients who underwent both medical and surgical management (64.96%). Overall mortality among CAM patients was found to be 38.32%. In conclusion, this study found a high incidence of CAM with a high mortality rate. Optimal glycemic control and early identification of mucormycosis should be the priority to reduce the morbidity and mortality related to CAM.
ER -
HUSSAIN, Mohammad Salman, Harveen BAXI, Abanoub RIAD, Jitka KLUGAROVÁ, Andrea POKORNÁ, Simona SLEZÁKOVÁ, Radim LÍČENÍK, Abul Kalam NAJMI a Miloslav KLUGAR. COVID-19-Associated Mucormycosis (CAM): An Updated Evidence Mapping. \textit{Environmental Research and Public Health}. Basel: MDPI, 2021, roč.~18, č.~19, s.~1-18. ISSN~1660-4601. Dostupné z: https://dx.doi.org/10.3390/ijerph181910340.
|
